Review about gabapentin misuse, interactions, contraindications and side effects

Gabriel C Quintero, Gabriel C Quintero

Abstract

The current work is targeted to review the risks of gabapentin misuse, its potential interactions with other drugs, side effects and use contraindications. This review consists of a total of 99 biographical references (from the year 1983 to 2016). A publication search of PubMed was performed from January 1983 to December 2016. It included animal studies, clinical studies, case studies and reviews related to gabapentin misuse, potential interactions, side effects and use contraindications. The search terms were gabapentin, anticonvulsant and antiepileptic. In general, it seems that gabapentin has risks of being misused based on the increased level of prescriptions, related fatalities, recreational misuse and higher doses of self-administration. The main reasons for gabapentin misuse are as follows: getting high, alleviating opioid withdrawal symptoms and potentiating methadone effects. Some of the main substances that interact with gabapentin are morphine, caffeine, losartan, ethacrynic acid, phenytoin, mefloquine and magnesium oxide. Some of the side effects caused by gabapentin are teratogenicity, hypoventilation, respiratory failure and myopathy. Finally, reports in general contraindicate the use of gabapentin in conditions such as myasthenia gravis and myoclonus.

Keywords: contraindications; gabapentin; interactions; misuse; side effects.

Conflict of interest statement

Disclosure The author reports no conflicts of interest in this work.

References

    1. Bockbrader HN, Wesche D, Miller R, Chapel S, Janiczek N, Burger P. A comparison of the pharmacokinetics and pharmacodynamics of pregabalin and gabapentin. Clin Pharmacokinet. 2010;49(10):661–669.
    1. Dickenson AH, Ghandehari J. Anticonvulsants and anti-depressants. Handb Exp Pharmacol. 2007;(177):145–177.
    1. Landmark CJ. Targets for antiepileptic drugs in the synapse. Med Sci Monit. 2007;13:RA1–RA7.
    1. Rogawski MA, Loscher W. The neurobiology of antiepileptic drugs. Nat Rev Neurosci. 2004;5:553–564.
    1. Coderre TJ, Kumar N, Lefebvre CD, Yu JS. A comparison of the glutamate release inhibition and anti-allodynic effects of gabapentin, lamotrigine, and riluzole in a model of neuropathic pain. J Neurochem. 2007;100(5):1289–1299.
    1. Cunningham MO, Woodhall GL, Thompson SE, Dooley DJ, Jones RS. Dual effects of gabapentin and pregabalin on glutamate release at rat entorhinal synapses in vitro. Eur J Neurosci. 2004;20(6):1566–1576.
    1. Eroglu CAN, Susman MW, O’Rourke NA, et al. Gabapentin receptor a2d-1 is a neuronal thrombospondin receptor responsible for excitatory CNS synaptogenesis. Cell. 2009;139:380–392.
    1. Bauer CS, Tran-Van-Minh A, Kadurin I, Dolphin AC. A new look at calcium channel α2δ subunits. Curr Opin Neurobiol. 2010;20:1–9.
    1. Marais E, Klugbauer N, Hofmann F. Calcium channel alpha(2) delta subunits-structure and Gabapentin binding. Mol Pharmacol. 2001;59(5):1243–1248.
    1. Cai K, Nanga RP, Lamprou L, et al. The impact of gabapentin administration on brain GABA and glutamate concentrations: a 7T (1)H-MRS study. Neuropsychopharmacology. 2012;37(13):2764–2771.
    1. Jensen AA, Mosbacher J, Elg S, et al. The anticonvulsant gabapentin (neurontin) does not act through gamma-aminobutyric acid-B receptors. Mol Pharmacol. 2002;61(6):1377–1384.
    1. Lanneau C, Green A, Hirst WD, et al. Gabapentin is not a GABAB receptor agonist. Neuropharmacology. 2001;41(8):965–975.
    1. Hara K, Sata T. Inhibitory effect of gabapentin on N-methyl-D-aspartate receptors expressed in Xenopus oocytes. Acta Anaesthesiol Scand. 2007;51(1):122–128.
    1. Zhang YB, Guo ZD, Li MY, et al. Gabapentin effects on PKC-ERK1/2 signaling in the spinal cord of rats with formalin-induced visceral inflammatory pain. PLoS One. 2015;10(10):e0141142.
    1. Hengy H, Kolle EU. Determination of gabapentin in plasma and urine by high-performance liquid chromatography and pre-column labelling for ultraviolet detection. J Chromatogr. 1985;341(2):473–478.
    1. Vollmer KO, von Hodenberg A, Kolle EU. Pharmacokinetics and metabolism of gabapentin in rat, dog and man. Arzneimittelforschung. 1986;36(5):830–839.
    1. Reimann W. Inhibition by GABA, baclofen and gabapentin of dopamine release from rabbit caudate nucleus: are there common or different sites of action? Eur J Pharmacol. 1983;94(3–4):341–344.
    1. Schlicker E, Reimann W, Gothert M. Gabapentin decreases monoamine release without affecting acetylcholine release in the brain. Arzneimittelforschung. 1985;35(9):1347–1349.
    1. Bartoszyk GD, Hamer M. The genetic animal model of reflex epilepsy in the Mongolian gerbil: differential efficacy of new anticonvulsive drugs and prototype antiepileptics. Pharmacol Res Commun. 1987;19(6):429–440.
    1. Crawford P, Ghadiali E, Lane R, Blumhardt L, Chadwick D. Gabapentin as an antiepileptic drug in man. J Neurol Neurosurg Psychiatry. 1987;50(6):682–686.
    1. Ryback R, Ryback L. Gabapentin for behavioral dyscontrol. Am J Psychiatry. 1995;152(9):1399.
    1. Walden J, Hesslinger B. Value of old and new anticonvulsants in treatment of psychiatric diseases. Fortschr Neurol Psychiatr. 1995;63(8):320–335.
    1. Welty DF, Schielke GP, Rothstein JD. Potential treatment of amyotrophic lateral sclerosis with gabapentin: a hypothesis. Ann Pharmacother. 1995;29(11):1164–1167.
    1. Shimoyama M, Shimoyama N, Inturrisi CE, Elliott KJ. Gabapentin enhances the antinociceptive effects of spinal morphine in the rat tail-flick test. Pain. 1997;72(3):375–382.
    1. Rosner H, Rubin L, Kestenbaum A. Gabapentin adjunctive therapy in neuropathic pain states. Clin J Pain. 1996;12(1):56–58.
    1. Singh L, Field MJ, Ferris P, et al. The antiepileptic agent gabapentin (Neurontin) possesses anxiolytic-like and antinociceptive actions that are reversed by D-serine. Psychopharmacology (Berl) 1996;127(1):1–9.
    1. Segal AZ, Rordorf G. Gabapentin as a novel treatment for postherpetic neuralgia. Neurology. 1996;46(4):1175–1176.
    1. Mellick GA, Mellick LB. Management of restless legs syndrome with gabapentin (Neurontin) Sleep. 1996;19(3):224–226.
    1. Adler CH. Treatment of restless legs syndrome with gabapentin. Clin Neuropharmacol. 1997;20(2):148–151.
    1. Ryback RS, Brodsky L, Munasifi F. Gabapentin in bipolar disorder. J Neuropsychiatry Clin Neurosci. 1997;9(2):301.
    1. Gabapentin and pregabalin: abuse and addiction. Prescrire Int. 2012;21(128):152–154.
    1. Smith BH, Higgins C, Baldacchino A, Kidd B, Bannister J. Substance misuse of gabapentin. Br J Gen Pract. 2012;62(601):406–407.
    1. Spence D. Bad medicine: gabapentin and pregabalin. BMJ. 2013;347:f6747.
    1. Maskell PD. Gabapentin and pregabalin abuse by heroin users. Br Med J. 2013;347:f6747.
    1. Kruszewski SP, Paczynski RP, Kahn DA. Gabapentin-induced delirium and dependence. J Psychiatr Pract. 2009;15(4):314–319.
    1. Reccoppa L, Malcolm R, Ware M. Gabapentin abuse in inmates with prior history of cocaine dependence. Am J Addict. 2004;13(3):321–323.
    1. Smith RV, Lofwall MR, Havens JR. Abuse and diversion of gabapentin among nonmedical prescription opioid users in Appalachian Kentucky. Am J Psychiatry. 2015;172(5):487–488.
    1. Havens JR, Lofwall MR, Frost SD, Oser CB, Leukefeld CG, Crosby RA. Individual and network factors associated with prevalent hepatitis C infection among rural Appalachian injection drug users. Am J Public Health. 2013;103(1):e44–e52.
    1. Baird CR, Fox P, Colvin LA. Gabapentinoid abuse in order to potentiate the effect of methadone: a survey among substance misusers. Eur Addict Res. 2014;20(3):115–118.
    1. Schifano F, D’Offizi S, Piccione M, et al. Is there a recreational misuse potential for pregabalin? Analysis of anecdotal online reports in comparison with related gabapentin and clonazepam data. Psychother Psychosom. 2011;80(2):118–122.
    1. Hakkinen M, Vuori E, Kalso E, Gergov M, Ojanpera I. Profiles of pregabalin and gabapentin abuse by postmortem toxicology. Forensic Sci Int. 2014;241:1–6.
    1. Chiappini S, Schifano F. A decade of gabapentinoid misuse: an analysis of the European Medicines Agency’s ‘suspected adverse drug reactions’ Database. CNS Drugs. 2016;30(7):647–654.
    1. Bastiaens L, Galus J, Mazur C. Abuse of gabapentin is associated with opioid addiction. Psychiatr Q. 2016;87(4):763–767.
    1. Kapil V, Green JL, Le Lait MC, Wood DM, Dargan PI. Misuse of the gamma-aminobutyric acid analogues baclofen, gabapentin and pregabalin in the UK. Br J Clin Pharmacol. 2014;78(1):190–191.
    1. Prakash, Prabhu LV, Rai R, et al. Teratogenic effects of the anticonvulsant gabapentin in mice. Singapore Med J. 2008;49(1):47–53.
    1. Afshar M, Golalipour MJ. Teratogenic effects of gabapentin on neural tube and limb development in mice. Neurosciences (Riyadh) 2008;13(3):321–323.
    1. Afshar M, Hassanzadeh-Taheri MM, Moallem SA, Tamizi A, Golalipour MJ. Teratogenic effects of gabapentin on the skeletal system of Balb/C mice fetuses. Neurosciences (Riyadh) 2009;14(3):239–244.
    1. Catala Perez R, Gamez Lechuga M, Martinez-Lage Alvarez M, Anton Albisu A. Gabapentin-induced central hypoventilation. Med Clin (Barc) 2007;128(13):519.
    1. Batoon SB, Vela AT, Dave D, et al. Recurrent hypoventilation and respiratory failure during gabapentin therapy. J Am Geriatr Soc. 2001;49(4):498.
    1. Bekkelund SI, Lilleng H, Tønseth S. Gabapentin may cause reversible visual field constriction. BMJ. 2006;332(7551):1193.
    1. Tuccori M, Lombardo G, Lapi F, Vannacci A, Blandizzi C, Del Tacca M. Gabapentin-induced severe myopathy. Ann Pharmacother. 2007;41(7):1301–1305.
    1. Lipson J, Lavoie S, Zimmerman D. Gabapentin-induced myopathy in 2 patients on short daily hemodialysis. Am J Kidney Dis. 2005;45(6):E100–E104.
    1. Tandon VR, Mahajan V, Gillani ZH, Mahajan A. Pregabalin-induced self-harm behavior. Indian J Pharmacol. 2013;45(6):638–639.
    1. Patorno E, Bohn RL, Wahl PM, et al. Anticonvulsant medications and the risk of suicide, attempted suicide, or violent death. JAMA. 2010;303(14):1401–1409.
    1. Andersohn F, Schade R, Willich SN, Garbe E. Use of antiepileptic drugs in epilepsy and the risk of self-harm or suicidal behaviour. Neurology. 2010;9(75):335–340.
    1. Gibbons RD, Hur K, Brown CH, Mann JJ. Gabapentin and suicide attempts. Pharmacoepidemiol Drug Saf. 2010;19(12):1241–1247.
    1. Finsterer J, Zarrouk Mahjoub S. Mitochondrial toxicity of antiepileptic drugs and their tolerability in mitochondrial disorders. Expert Opin Drug Metab Toxicol. 2012;8(1):71–79.
    1. Sihoe AD, Lee TW, Wan IY, Thung KH, Yim AP. The use of gabapentin for post-operative and post-traumatic pain in thoracic surgery patients. Eur J Cardiothorac Surg. 2006;29(5):795–799.
    1. Petrere JA, Anderson JA. Developmental toxicity studies in mice, rats, and rabbits with the anticonvulsant gabapentin. Fundam Appl Toxicol. 1994;23(4):585–589.
    1. Montouris G. Gabapentin exposure in human pregnancy: results from the Gabapentin Pregnancy Registry. Epilepsy Behav. 2003;4(3):310–317.
    1. Verrotti A, Mencaroni E, Castagnino M, Zaccara G. Foetal safety of old and new antiepileptic drugs. Expert Opin Drug Saf. 2015;14(10):1563–1571.
    1. Hill DS, Wlodarczyk BJ, Palacios AM, Finnell RH. Teratogenic effects of antiepileptic drugs. Expert Rev Neurother. 2010;10(6):943–959.
    1. Ramsay RE.Gabapentin toxicity Levy RH, Mattson RH, Meldrum BS.Antiepileptic Drugs. 4th edNew York: Raven Press; 1995857–860.
    1. McLean MJ, Morrell MJ, Willmore LJ, et al. Safety and tolerability of gabapentin as adjunctive therapy in a large, multicenter study. Epilepsia. 1999;40(7):965–972.
    1. Canadillas-Hidalgo FM. The safety and tolerability profile of gabapentin in optimal doses. Rev Neurol. 2004;39(4):371–380.
    1. Comoglu T. The influence of administration route in the comparison of dosage forms. Arch Trauma Res. 2013;2(1):58–59.
    1. Aulton ME. Pharmaceutics: The Science of Dosage Form Design. Edinburgh; New York: Churchill Livingstone: 2002. pp. 197–210.
    1. Jankovic SM, Dostic M. Choice of antiepileptic drugs for the elderly: possible drug interactions and adverse effects. Expert Opin Drug Metab Toxicol. 2012;8(1):81–91.
    1. Patsalos PN. Drug interactions with the newer antiepileptic drugs (AEDs)–part 1: pharmacokinetic and pharmacodynamic interactions between AEDs. Clin Pharmacokinet. 2013;52(11):927–966.
    1. Diaz RA, Sancho J, Serratosa J. Antiepileptic drug interactions. Neurologist. 2008;14(6 suppl 1):S55–S65.
    1. Johannessen Landmark C, Patsalos PN. Drug interactions involving the new second- and third-generation antiepileptic drugs. Expert Rev Neurother. 2010;10(1):119–140.
    1. Lukawski K, Swiderska G, Czuczwar SJ. Effect of combined treatment with diuretics and gabapentin on convulsive threshold in mice. Acta Pol Pharm. 2013;70(1):147–152.
    1. Eldon MA, Underwood BA, Randinitis EJ, Sedman AJ. Gabapentin does not interact with a contraceptive regimen of norethindrone acetate and ethinyl estradiol. Neurology. 1998;50(4):1146–1148.
    1. Radulovic LL, Wilder BJ, Leppik IE, et al. Lack of interaction of gabapentin with carbamazepine or valproate. Epilepsia. 1994;35(1):155–161.
    1. Hooper WD, Kavanagh MC, Herkes GK, Eadie MJ. Lack of a pharmacokinetic interaction between phenobarbitone and gabapentin. Br J Clin Pharmacol. 1991;31(2):171–174.
    1. Luszczki JJ. Isobolographic analysis of interaction between drugs with nonparallel dose-response relationship curves: a practical application. Naunyn Schmiedebergs Arch Pharmacol. 2007;375(2):105–114.
    1. Papathanasiou T, Juul RV, Gabel-Jensen C, Kreilgaard M, Lund TM. Population pharmacokinetic modelling of morphine, gabapentin and their combination in the rat. Pharm Res. 2016;33(11):2630–2643.
    1. Papathanasiou T, Juul RV, Heegaard AM, Kreilgaard M, Lund TM. Co-administration of morphine and gabapentin leads to dose dependent synergistic effects in a rat model of postoperative pain. Eur J Pharm Sci. 2016;82:97–105.
    1. Eckhardt K, Ammon S, Hofmann U, Riebe A, Gugeler N, Mikus G. Gabapentin enhances the analgesic effect of morphine in healthy volunteers. Anesth Analg. 2000;91(1):185–191.
    1. Lukawski K, Janowska A, Jakubus T, Raszewski G, Czuczwar SJ. Combined treatment with gabapentin and drugs affecting the renin-angiotensin system against electroconvulsions in mice. Eur J Pharmacol. 2013;706(1–3):92–97.
    1. Borobia-Perez AM, Fernandez-Capitan C, Carcas-Sansuan AJ. Psicosis, alucinaciones visuales y deterioro de la función renal secundarias a la interacción gabapentina-morfina [Psychosis, visual hallucinations and worsening renal function due to a gabapentine-morphine interaction] Rev Neurol. 2008;47(6):332–333. Spanish.
    1. Goel R, Goel A, Kumar Y. Influence of carvedilol on anticonvulsant effect of gabapentin. Acta Neurol Belg. 2011;111(4):296–305.
    1. Granados-Soto V, Arguelles CF. Synergic antinociceptive interaction between tramadol and gabapentin after local, spinal and systemic administration. Pharmacology. 2005;74(4):200–208.
    1. Ortega-Varela LF, Herrera JE, Medina-Santillan R, Reyes-Garcia G, Rocha-Gonzalez HI, Granados-Soto V. Synergistic interaction between gabapentin and metamizol in the rat formalin test. Proc West Pharmacol Soc. 2004;47:80–83.
    1. Rizwan AN, Ali A, Dua Y, Pal SN, Pillai KK. Effects of gabapentin and antidepressant drug combinations on convulsions and memory in mice. Pol J Pharmacol. 2003;55(6):965–971.
    1. Sanchez-Romero A, Duran-Quintana JA, Garcia-Delgado R, Margarito-Rangel C, Poveda-Andres JL. Possible gabapentin phenytoin interaction. Rev Neurol. 2002;34(10):952–953.
    1. Nevin RL, Pietrusiak PP, Caci JB. Prevalence of contraindications to mefloquine use among USA military personnel deployed to Afghanistan. Malar J. 2008;7:30.
    1. Franco-Perez J, Ballesteros-Zebadua P, Manjarrez-Marmolejo J. Anticonvulsant effects of mefloquine on generalized tonic-clonic seizures induced by two acute models in rats. BMC Neurosci. 2015;16:7.
    1. Yagi T, Naito T, Mino Y, Umemura K, Kawakami J. Impact of concomitant antacid administration on gabapentin plasma exposure and oral bioavailability in healthy adult subjects. Drug Metab Pharmacokinet. 2012;27(2):248–254.
    1. Richens A. Clinical pharmacokinetics of gabapentin. In: Chadwick D, editor. New Trends in Epilepsy Management: The Role of Gabapentin. London, UK: Royal Society of Medicine Service; 1993. pp. 41–46.
    1. Shemenski J. Cimetidine as a novel adjunctive treatment for early stage Lyme disease. Med Hypotheses. 2016 Apr 9; Epub.
    1. Hurley RW, Chatterjea D, Rose Feng M, Taylor CP, Hammond DL. Gabapentin and pregabalin can interact synergistically with naproxen to produce antihyperalgesia. Anesthesiology. 2002;97(5):1263–1273.
    1. Duggan KC, Walters MJ, Musee J, et al. Molecular basis for cyclooxygenase inhibition by the non-steroidal anti-inflammatory drug naproxen. J Biol Chem. 2010;285(45):34950–34959.
    1. Joel JJ, Musthafa MM, Shastry CS. A study on drug related problems and pharmacist intervention in patients undergoing haemodialysis in a tertiary care hospital. Int Res J Pharm App Sci. 2013;3(5):263–265.
    1. Garg JP, Chasan-Taber S, Blair A, et al. Effects of sevelamer and calcium-based phosphate binders on uric acid concentrations in patients undergoing hemodialysis: a randomized clinical trial. Arthritis Rheum. 2005;52(1):290–295.
    1. Boneva N, Brenner T, Argov Z. Gabapentin may be hazardous in myasthenia gravis. Muscle Nerve. 2000;23(8):1204–1208.
    1. Koide Y, Ikeda H, Inoue Y. Development or worsening of myoclonus associated with gabapentin therapy. Rinsho Shinkeigaku. 2009;49(6):342–347.
    1. United States National Library of Medicine Act Gabapentin Available from: Accessed June 1, 2016a
    1. United States National Library of Medicine Drug Information Portal. [Accessed June 1, 2016]. Available from: .

Source: PubMed

Sponsorer och medarbetare

Medicinska tillstånd

Läkemedelsinterventioner

3
Prenumerera